Starting age of oestrogen‐progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index
Objective Osteoporosis is an important health issue in patients with Turner syndrome (TS), and oestrogen sufficiency has been implicated in increased bone mineral density (BMD); however, the impact of the starting age of hormone replacement therapy (HRT) on bone mineral density remains unclear, part...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2021-07, Vol.95 (1), p.84-91 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 91 |
|---|---|
| container_issue | 1 |
| container_start_page | 84 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 95 |
| creator | Nishigaki, Satsuki Itonaga, Tomoyo Hasegawa, Yukihiro Kawai, Masanobu |
| description | Objective
Osteoporosis is an important health issue in patients with Turner syndrome (TS), and oestrogen sufficiency has been implicated in increased bone mineral density (BMD); however, the impact of the starting age of hormone replacement therapy (HRT) on bone mineral density remains unclear, particularly during young adulthood.
Design
A retrospective study from three tertiary care hospitals in Japan.
Patients
One hundred and three patients with TS aged between 18 and 30 years of age who underwent dual‐energy X‐ray absorptiometry.
Measurements
Anthropometric parameters, lumbar bone mineral density (L‐BMD), including areal BMD (aBMD) and volumetric BMD (vBMD), karyotypes, the presence of spontaneous menarche, the starting ages of oestrogen replacement therapy (ERT) and oestrogen‐progestin therapy (EPT), and the duration between starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy were investigated. vBMD was calculated based on the Kröger method.
Results
aBMD was lower in young adults with TS than in an age‐matched reference population. L‐BMD positively correlated with weight and body mass index (BMI). L‐BMD was higher in subjects with spontaneous menarche (N = 22) than in those without. A dose escalation regimen of oestrogen replacement therapy was used in 84% of subjects without spontaneous menarche (N = 81). The starting age of oestrogen replacement therapy and the duration between the starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy negatively and independently correlated with aBMD, but not with vBMD, after adjustment with age and BMI. The starting age of oestrogen‐progestin therapy negatively correlated with L‐BMD independent of age and BMI.
Conclusions
Early introduction of hormone replacement therapy, particularly oestrogen‐progestin therapy, is important to accrue better L‐BMD in young adults with TS. |
| doi_str_mv | 10.1111/cen.14484 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2515687988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2536726739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-d83dfd48ff1de1762d8d2e556b8162ca20290f4f0e6b4e60e074e52bf2413c6b3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhS0EopfCghdAltjAIq3_4vgu0VX5kSpYUNaRE09uXSX2JXZasuMR-iB9Kp6ESVNYIOGFPZI_nzmeQ8hLzk44rtMWwglXyqhHZMOlLgshdPmYbJhkrGBaqyPyLKUrxlhpWPWUHElpKqEE35C7r9mO2Yc9tXugsaMRUh7jHsKvn7eHpUh4S_MljPYwU59ogL3N_hr6mdqUYuttBkdvfL6kTQxABx-Q7amDkHzGJ4HOcVoauKnPaSUvphEpmubgxjgAQg4OgFvIi4nFiw0OBd1MB2xzD_x4Tp50tk_w4uE8Jt_en13sPhbnXz582r07L1pZSlU4I13nlOk67oBXWjjjBJSlbgzXorWCiS3rVMdANwo0A1YpKEXTCcVlqxt5TN6sujiA7xNOoB58aqHvbYA4pVqUvNSm2hqD6Ot_0KuIf0N3SEldCV3JLVJvV6odY0ojdPVh9IMd55qzeomwxgjr-wiRffWgODUDuL_kn8wQOF2BG9_D_H-lenf2eZX8DXX0qew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2536726739</pqid></control><display><type>article</type><title>Starting age of oestrogen‐progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Nishigaki, Satsuki ; Itonaga, Tomoyo ; Hasegawa, Yukihiro ; Kawai, Masanobu</creator><creatorcontrib>Nishigaki, Satsuki ; Itonaga, Tomoyo ; Hasegawa, Yukihiro ; Kawai, Masanobu</creatorcontrib><description>Objective
Osteoporosis is an important health issue in patients with Turner syndrome (TS), and oestrogen sufficiency has been implicated in increased bone mineral density (BMD); however, the impact of the starting age of hormone replacement therapy (HRT) on bone mineral density remains unclear, particularly during young adulthood.
Design
A retrospective study from three tertiary care hospitals in Japan.
Patients
One hundred and three patients with TS aged between 18 and 30 years of age who underwent dual‐energy X‐ray absorptiometry.
Measurements
Anthropometric parameters, lumbar bone mineral density (L‐BMD), including areal BMD (aBMD) and volumetric BMD (vBMD), karyotypes, the presence of spontaneous menarche, the starting ages of oestrogen replacement therapy (ERT) and oestrogen‐progestin therapy (EPT), and the duration between starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy were investigated. vBMD was calculated based on the Kröger method.
Results
aBMD was lower in young adults with TS than in an age‐matched reference population. L‐BMD positively correlated with weight and body mass index (BMI). L‐BMD was higher in subjects with spontaneous menarche (N = 22) than in those without. A dose escalation regimen of oestrogen replacement therapy was used in 84% of subjects without spontaneous menarche (N = 81). The starting age of oestrogen replacement therapy and the duration between the starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy negatively and independently correlated with aBMD, but not with vBMD, after adjustment with age and BMI. The starting age of oestrogen‐progestin therapy negatively correlated with L‐BMD independent of age and BMI.
Conclusions
Early introduction of hormone replacement therapy, particularly oestrogen‐progestin therapy, is important to accrue better L‐BMD in young adults with TS.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/cen.14484</identifier><identifier>PMID: 33872421</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Absorptiometry, Photon ; Adolescent ; Adult ; Age ; Body Mass Index ; Bone Density ; Bone mineral density ; Estrogen Replacement Therapy ; Estrogens ; Estrogens - therapeutic use ; Female ; Genetic disorders ; Hormone replacement therapy ; Humans ; Karyotypes ; Menarche ; Osteoporosis ; Progestin ; Progestins - therapeutic use ; Retrospective Studies ; Turner syndrome ; Turner Syndrome - drug therapy ; Turner's syndrome ; Young Adult ; Young adults</subject><ispartof>Clinical endocrinology (Oxford), 2021-07, Vol.95 (1), p.84-91</ispartof><rights>2021 John Wiley & Sons Ltd</rights><rights>2021 John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-d83dfd48ff1de1762d8d2e556b8162ca20290f4f0e6b4e60e074e52bf2413c6b3</citedby><cites>FETCH-LOGICAL-c3534-d83dfd48ff1de1762d8d2e556b8162ca20290f4f0e6b4e60e074e52bf2413c6b3</cites><orcidid>0000-0003-4466-1559 ; 0000-0003-4894-5356 ; 0000-0002-0668-1754</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcen.14484$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcen.14484$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33872421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishigaki, Satsuki</creatorcontrib><creatorcontrib>Itonaga, Tomoyo</creatorcontrib><creatorcontrib>Hasegawa, Yukihiro</creatorcontrib><creatorcontrib>Kawai, Masanobu</creatorcontrib><title>Starting age of oestrogen‐progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Objective
Osteoporosis is an important health issue in patients with Turner syndrome (TS), and oestrogen sufficiency has been implicated in increased bone mineral density (BMD); however, the impact of the starting age of hormone replacement therapy (HRT) on bone mineral density remains unclear, particularly during young adulthood.
Design
A retrospective study from three tertiary care hospitals in Japan.
Patients
One hundred and three patients with TS aged between 18 and 30 years of age who underwent dual‐energy X‐ray absorptiometry.
Measurements
Anthropometric parameters, lumbar bone mineral density (L‐BMD), including areal BMD (aBMD) and volumetric BMD (vBMD), karyotypes, the presence of spontaneous menarche, the starting ages of oestrogen replacement therapy (ERT) and oestrogen‐progestin therapy (EPT), and the duration between starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy were investigated. vBMD was calculated based on the Kröger method.
Results
aBMD was lower in young adults with TS than in an age‐matched reference population. L‐BMD positively correlated with weight and body mass index (BMI). L‐BMD was higher in subjects with spontaneous menarche (N = 22) than in those without. A dose escalation regimen of oestrogen replacement therapy was used in 84% of subjects without spontaneous menarche (N = 81). The starting age of oestrogen replacement therapy and the duration between the starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy negatively and independently correlated with aBMD, but not with vBMD, after adjustment with age and BMI. The starting age of oestrogen‐progestin therapy negatively correlated with L‐BMD independent of age and BMI.
Conclusions
Early introduction of hormone replacement therapy, particularly oestrogen‐progestin therapy, is important to accrue better L‐BMD in young adults with TS.</description><subject>Absorptiometry, Photon</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Body Mass Index</subject><subject>Bone Density</subject><subject>Bone mineral density</subject><subject>Estrogen Replacement Therapy</subject><subject>Estrogens</subject><subject>Estrogens - therapeutic use</subject><subject>Female</subject><subject>Genetic disorders</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Karyotypes</subject><subject>Menarche</subject><subject>Osteoporosis</subject><subject>Progestin</subject><subject>Progestins - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Turner syndrome</subject><subject>Turner Syndrome - drug therapy</subject><subject>Turner's syndrome</subject><subject>Young Adult</subject><subject>Young adults</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1TAQhS0EopfCghdAltjAIq3_4vgu0VX5kSpYUNaRE09uXSX2JXZasuMR-iB9Kp6ESVNYIOGFPZI_nzmeQ8hLzk44rtMWwglXyqhHZMOlLgshdPmYbJhkrGBaqyPyLKUrxlhpWPWUHElpKqEE35C7r9mO2Yc9tXugsaMRUh7jHsKvn7eHpUh4S_MljPYwU59ogL3N_hr6mdqUYuttBkdvfL6kTQxABx-Q7amDkHzGJ4HOcVoauKnPaSUvphEpmubgxjgAQg4OgFvIi4nFiw0OBd1MB2xzD_x4Tp50tk_w4uE8Jt_en13sPhbnXz582r07L1pZSlU4I13nlOk67oBXWjjjBJSlbgzXorWCiS3rVMdANwo0A1YpKEXTCcVlqxt5TN6sujiA7xNOoB58aqHvbYA4pVqUvNSm2hqD6Ot_0KuIf0N3SEldCV3JLVJvV6odY0ojdPVh9IMd55qzeomwxgjr-wiRffWgODUDuL_kn8wQOF2BG9_D_H-lenf2eZX8DXX0qew</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Nishigaki, Satsuki</creator><creator>Itonaga, Tomoyo</creator><creator>Hasegawa, Yukihiro</creator><creator>Kawai, Masanobu</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4466-1559</orcidid><orcidid>https://orcid.org/0000-0003-4894-5356</orcidid><orcidid>https://orcid.org/0000-0002-0668-1754</orcidid></search><sort><creationdate>202107</creationdate><title>Starting age of oestrogen‐progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index</title><author>Nishigaki, Satsuki ; Itonaga, Tomoyo ; Hasegawa, Yukihiro ; Kawai, Masanobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-d83dfd48ff1de1762d8d2e556b8162ca20290f4f0e6b4e60e074e52bf2413c6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Absorptiometry, Photon</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Body Mass Index</topic><topic>Bone Density</topic><topic>Bone mineral density</topic><topic>Estrogen Replacement Therapy</topic><topic>Estrogens</topic><topic>Estrogens - therapeutic use</topic><topic>Female</topic><topic>Genetic disorders</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Karyotypes</topic><topic>Menarche</topic><topic>Osteoporosis</topic><topic>Progestin</topic><topic>Progestins - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Turner syndrome</topic><topic>Turner Syndrome - drug therapy</topic><topic>Turner's syndrome</topic><topic>Young Adult</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishigaki, Satsuki</creatorcontrib><creatorcontrib>Itonaga, Tomoyo</creatorcontrib><creatorcontrib>Hasegawa, Yukihiro</creatorcontrib><creatorcontrib>Kawai, Masanobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishigaki, Satsuki</au><au>Itonaga, Tomoyo</au><au>Hasegawa, Yukihiro</au><au>Kawai, Masanobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Starting age of oestrogen‐progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2021-07</date><risdate>2021</risdate><volume>95</volume><issue>1</issue><spage>84</spage><epage>91</epage><pages>84-91</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><abstract>Objective
Osteoporosis is an important health issue in patients with Turner syndrome (TS), and oestrogen sufficiency has been implicated in increased bone mineral density (BMD); however, the impact of the starting age of hormone replacement therapy (HRT) on bone mineral density remains unclear, particularly during young adulthood.
Design
A retrospective study from three tertiary care hospitals in Japan.
Patients
One hundred and three patients with TS aged between 18 and 30 years of age who underwent dual‐energy X‐ray absorptiometry.
Measurements
Anthropometric parameters, lumbar bone mineral density (L‐BMD), including areal BMD (aBMD) and volumetric BMD (vBMD), karyotypes, the presence of spontaneous menarche, the starting ages of oestrogen replacement therapy (ERT) and oestrogen‐progestin therapy (EPT), and the duration between starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy were investigated. vBMD was calculated based on the Kröger method.
Results
aBMD was lower in young adults with TS than in an age‐matched reference population. L‐BMD positively correlated with weight and body mass index (BMI). L‐BMD was higher in subjects with spontaneous menarche (N = 22) than in those without. A dose escalation regimen of oestrogen replacement therapy was used in 84% of subjects without spontaneous menarche (N = 81). The starting age of oestrogen replacement therapy and the duration between the starting ages of oestrogen replacement therapy and oestrogen‐progestin therapy negatively and independently correlated with aBMD, but not with vBMD, after adjustment with age and BMI. The starting age of oestrogen‐progestin therapy negatively correlated with L‐BMD independent of age and BMI.
Conclusions
Early introduction of hormone replacement therapy, particularly oestrogen‐progestin therapy, is important to accrue better L‐BMD in young adults with TS.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33872421</pmid><doi>10.1111/cen.14484</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4466-1559</orcidid><orcidid>https://orcid.org/0000-0003-4894-5356</orcidid><orcidid>https://orcid.org/0000-0002-0668-1754</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2021-07, Vol.95 (1), p.84-91 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2515687988 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Absorptiometry, Photon Adolescent Adult Age Body Mass Index Bone Density Bone mineral density Estrogen Replacement Therapy Estrogens Estrogens - therapeutic use Female Genetic disorders Hormone replacement therapy Humans Karyotypes Menarche Osteoporosis Progestin Progestins - therapeutic use Retrospective Studies Turner syndrome Turner Syndrome - drug therapy Turner's syndrome Young Adult Young adults |
| title | Starting age of oestrogen‐progestin therapy is negatively associated with bone mineral density in young adults with Turner syndrome independent of age and body mass index |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T13%3A07%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Starting%20age%20of%20oestrogen%E2%80%90progestin%20therapy%20is%20negatively%20associated%20with%20bone%20mineral%20density%20in%20young%20adults%20with%20Turner%20syndrome%20independent%20of%20age%20and%20body%20mass%20index&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Nishigaki,%20Satsuki&rft.date=2021-07&rft.volume=95&rft.issue=1&rft.spage=84&rft.epage=91&rft.pages=84-91&rft.issn=0300-0664&rft.eissn=1365-2265&rft_id=info:doi/10.1111/cen.14484&rft_dat=%3Cproquest_cross%3E2536726739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2536726739&rft_id=info:pmid/33872421&rfr_iscdi=true |